{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:41:33Z","timestamp":1773279693335,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) have similar initial histological findings; however, their prognoses are distinct. Therefore, it is of great importance to discriminate FSGS from MCD in the early phase of disease and predict clinical prognosis. A discovery set of 184 urine samples (61 healthy control, 80 MCD, and 43 FSGS) and a validation set of 61 urine samples (12 healthy control, 26 MCD, and 23 FSGS) were collected at the time of kidney biopsy. Metabolic profiles were examined using nuclear magnetic resonance spectroscopy. Of 70 urinary metabolites, myo-inositol was significantly higher in FSGS patients than in control patients (discovery set, 2.34-fold, P\u2009&lt;\u20090.001; validation set, 2.35-fold, P\u2009=\u20090.008) and MCD patients (discovery set, 2.48-fold, P\u2009=\u20090.002; validation set, 1.69-fold, P\u2009=\u20090.042). Myo-inositol showed an inverse relationship with the initial estimated glomerular filtration rate (eGFR) and was associated with the plasma level of soluble urokinase-type plasminogen activator receptor in FSGS patients. Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an <jats:italic>in vitro<\/jats:italic> FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR. Furthermore, urinary myo-inositol exhibited an increase in the power to discriminate FSGS patients, and its addition could better predict the response to initial treatment. In conclusion, urinary myo-inositol may be an important indicator in the diagnosis and treatment of FSGS patients.<\/jats:p>","DOI":"10.1038\/s41598-019-51276-9","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:04:04Z","timestamp":1570788244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis"],"prefix":"10.1038","volume":"9","author":[{"given":"Jung Nam","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seong","family":"Hyeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Wook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hee","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soie","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-1265","authenticated-orcid":false,"given":"Hunjoo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-7852","authenticated-orcid":false,"given":"Dong Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-1260","authenticated-orcid":false,"given":"Jung Pyo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geum-Sook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"51276_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2215\/CJN.00710805","volume":"1","author":"S Swaminathan","year":"2006","unstructured":"Swaminathan, S. et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 1, 483\u2013487 (2006).","journal-title":"Clin J Am Soc Nephrol"},{"key":"51276_CR2","first-page":"5679518","volume":"2019","author":"JM Lee","year":"2019","unstructured":"Lee, J. M. et al. Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis. J Immunol Res 2019, 5679518 (2019).","journal-title":"J Immunol Res"},{"key":"51276_CR3","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","volume":"23","author":"C Wei","year":"2012","unstructured":"Wei, C. et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23, 2051\u20132059 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"51276_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/TP.0b013e3182977ab1","volume":"96","author":"CR Franco Palacios","year":"2013","unstructured":"Franco Palacios, C. R. et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96, 394\u2013399 (2013).","journal-title":"Transplantation"},{"key":"51276_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ki.2014.346","volume":"87","author":"JM Spinale","year":"2015","unstructured":"Spinale, J. M. et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87, 564\u2013574 (2015).","journal-title":"Kidney Int"},{"key":"51276_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/j.1523-1755.2004.00563.x","volume":"65","author":"MB Stokes","year":"2004","unstructured":"Stokes, M. B., Markowitz, G. S., Lin, J., Valeri, A. M. & D\u2019Agati, V. D. Glomerular tip lesion: a distinct entity within the minimal change disease\/focal segmental glomerulosclerosis spectrum. Kidney Int 65, 1690\u20131702 (2004).","journal-title":"Kidney Int"},{"key":"51276_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nrneph.2016.147","volume":"12","author":"RJ Maas","year":"2016","unstructured":"Maas, R. J., Deegens, J. K., Smeets, B., Moeller, M. J. & Wetzels, J. F. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol 12, 768\u2013776 (2016).","journal-title":"Nat Rev Nephrol"},{"key":"51276_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2012070734","volume":"24","author":"J Hogan","year":"2013","unstructured":"Hogan, J. & Radhakrishnan, J. The treatment of minimal change disease in adults. J Am Soc Nephrol 24, 702\u2013711 (2013).","journal-title":"J Am Soc Nephrol"},{"key":"51276_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0272-6386(12)80128-4","volume":"23","author":"SM Korbet","year":"1994","unstructured":"Korbet, S. M., Schwartz, M. M. & Lewis, E. J. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 23, 773\u2013783 (1994).","journal-title":"Am J Kidney Dis"},{"key":"51276_CR10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","volume":"15","author":"MJ Chun","year":"2004","unstructured":"Chun, M. J., Korbet, S. M., Schwartz, M. M. & Lewis, E. J. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15, 2169\u20132177 (2004).","journal-title":"J Am Soc Nephrol"},{"key":"51276_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.abb.2015.10.006","volume":"589","author":"C Barrios","year":"2016","unstructured":"Barrios, C., Spector, T. D. & Menni, C. Blood, urine and faecal metabolite profiles in the study of adult renal disease. Arch Biochem Biophys 589, 81\u201392 (2016).","journal-title":"Arch Biochem Biophys"},{"key":"51276_CR12","doi-asserted-by":"publisher","first-page":"R199","DOI":"10.1186\/ar3530","volume":"13","author":"LE Romick-Rosendale","year":"2011","unstructured":"Romick-Rosendale, L. E. et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther 13, R199 (2011).","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"51276_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-S1-S14","volume":"6","author":"X Gao","year":"2012","unstructured":"Gao, X. et al. Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst Biol 6(Suppl 1), S14 (2012).","journal-title":"BMC Syst Biol"},{"key":"51276_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.6061\/clinics\/2012(04)10","volume":"67","author":"W Sui","year":"2012","unstructured":"Sui, W. et al. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy. Clinics 67, 363\u2013373 (2012).","journal-title":"Clinics"},{"key":"51276_CR15","doi-asserted-by":"publisher","first-page":"e78531","DOI":"10.1371\/journal.pone.0078531","volume":"8","author":"X Hao","year":"2013","unstructured":"Hao, X. et al. Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics. PloS one 8, e78531 (2013).","journal-title":"PloS one"},{"key":"51276_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.chroma.2016.05.058","volume":"1453","author":"JE Lee","year":"2016","unstructured":"Lee, J. E. et al. Systematic biomarker discovery and coordinative validation for different primary nephrotic syndromes using gas chromatography-mass spectrometry. J Chromatogr A 1453, 105\u2013115 (2016).","journal-title":"J Chromatogr A"},{"key":"51276_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.biochi.2013.05.011","volume":"95","author":"ML Croze","year":"2013","unstructured":"Croze, M. L. & Soulage, C. O. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95, 1811\u20131827 (2013).","journal-title":"Biochimie"},{"key":"51276_CR18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/ndt\/gfq554","volume":"26","author":"JY Choi","year":"2011","unstructured":"Choi, J. Y. et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 26, 1304\u20131313 (2011).","journal-title":"Nephrol Dial Transplant"},{"key":"51276_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/ki.2013.497","volume":"85","author":"MA Niewczas","year":"2014","unstructured":"Niewczas, M. A. et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 85, 1214\u20131224 (2014).","journal-title":"Kidney Int"},{"key":"51276_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/TP.0000000000000039","volume":"98","author":"B Dieme","year":"2014","unstructured":"Dieme, B. et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. Transplantation 98, 195\u2013201 (2014).","journal-title":"Transplantation"},{"key":"51276_CR21","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/ndt\/gfy020","volume":"33","author":"RB Gil","year":"2018","unstructured":"Gil, R. B. et al. Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate. Nephrol Dial Transplant 33, 2156\u20132164 (2018).","journal-title":"Nephrol Dial Transplant"},{"key":"51276_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1681\/ASN.2016070744","volume":"28","author":"RK Dutta","year":"2017","unstructured":"Dutta, R. K. et al. Beneficial Effects of Myo-Inositol Oxygenase Deficiency in Cisplatin-Induced AKI. J Am Soc Nephrol 28, 1421\u20131436 (2017).","journal-title":"J Am Soc Nephrol"},{"key":"51276_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1681\/ASN.2014111099","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula, P. et al. A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. J Am Soc Nephrol 27, 1175\u20131188 (2016).","journal-title":"J Am Soc Nephrol"},{"key":"51276_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0009-8981(76)90097-8","volume":"71","author":"E Pitkanen","year":"1976","unstructured":"Pitkanen, E. Changes in serum and urinary myo-inositol levels in chronic glomerulonephritis. Clinica chimica acta 71, 461\u2013468 (1976).","journal-title":"Clinica chimica acta"},{"key":"51276_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.23876\/j.krcp.2018.37.3.210","volume":"37","author":"SY Min","year":"2018","unstructured":"Min, S. Y., Ha, D. S. & Ha, T. S. Puromycin aminonucleoside triggers apoptosis in podocytes by inducing endoplasmic reticulum stress. Kidney Res Clin Pract 37, 210\u2013221 (2018).","journal-title":"Kidney Res Clin Pract"},{"key":"51276_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.krcp.2016.09.003","volume":"35","author":"HA Jo","year":"2016","unstructured":"Jo, H. A. et al. The role of local IL6\/JAK2\/STAT3 signaling in high glucose-induced podocyte hypertrophy. Kidney Res Clin Pract 35, 212\u2013218 (2016).","journal-title":"Kidney Res Clin Pract"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51276-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:31:47Z","timestamp":1671287507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51276-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51276"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51276-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14707"}}